Clearside Biomedical, Inc. (CLSD)
$
0.43
Key metrics
Financial statements
Free cash flow per share
-0.2855
Market cap
33.4 Million
Price to sales ratio
8.0263
Debt to equity
-0.0109
Current ratio
3.8677
Income quality
0.7840
Average inventory
0
ROE
0.6587
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Clearside Biomedical, Inc. is a biopharmaceutical company that aims to transform the delivery of therapies to the back of the eye by utilizing the suprachoroidal space. Among its offerings is XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension designed to treat uveitis macular edema. The company is also advancing the development of CLS-AX, an axitinib injectable suspension currently undergoing Phase 1/2a clinical trials, as well as CLS-301, an integrin inhibitor suspension targeted at treating diabetic macular edema and macular degeneration. The cost of revenue for the company is $149,000.00 showcasing its production and operational expenses. In terms of financial performance, the net income ratio is -20.64 reflecting the company’s profitability margin. The total costs and expenses for the company are $30,546,000.00 indicating its overall spending. Furthermore, the weighted average number of diluted shares outstanding is 73,803,348.00 which reflects potential dilution effects. The company reported an income before tax of -$34,352,000.00 showcasing its pre-tax profitability. Having been incorporated in 2011, Clearside Biomedical is headquartered in Alpharetta, Georgia, and collaborates with notable partners such as Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. In the investment landscape, Clearside Biomedical's stock is affordable at $0.83 making it suitable for budget-conscious investors. The stock has an average trading volume of 4,472,341.00 indicating moderate liquidity in the market. With a market capitalization of $33,437,537.00 the company is classified as a small-cap player, positioning it as a significant entity in the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within this domain. Additionally, it belongs to the Healthcare sector, which plays a crucial role in advancing medical therapies and technologies that have the potential to improve patient outcomes and quality of life.
Is Clearside Biomedical, Inc. (CLSD) a good investment?
Investing in Clearside Biomedical, Inc. (CLSD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Clearside Biomedical, Inc. (CLSD)'s stock forecast?
Analysts predict Clearside Biomedical, Inc. stock to fluctuate between $0.29 (low) and $1.65 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Clearside Biomedical, Inc.'s market capitalization?
As of 2025-08-19, Clearside Biomedical, Inc.'s market cap is $33,437,537, based on 78,510,300 outstanding shares.
How does Clearside Biomedical, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Clearside Biomedical, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Clearside Biomedical, Inc. (CLSD) stock?
To buy Clearside Biomedical, Inc. (CLSD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CLSD. Place an order (Market, Limit, etc.).
What is the best time to invest in Clearside Biomedical, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Clearside Biomedical, Inc. perform in the last earnings report?
Revenue: $1,664,000 | EPS: -$0.47 | Growth: -11.32%.
Where can I find Clearside Biomedical, Inc.'s investor relations reports?
Visit https://www.clearsidebio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Clearside Biomedical, Inc.?
You can explore historical data from here
What is the all-time high and low for Clearside Biomedical, Inc. stock?
All-time high: $7.73 (2021-08-30) | All-time low: $0.29 (2025-07-21).
What are the key trends affecting Clearside Biomedical, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
11 days ago
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.1 per share a year ago.
globenewswire.com
a month ago
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME).
globenewswire.com
a month ago
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases -
globenewswire.com
2 months ago
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the use of its SCS delivery platform will be featured in multiple presentations at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025 in Las Vegas, Nevada.
zacks.com
3 months ago
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com
3 months ago
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m.
zacks.com
3 months ago
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.
globenewswire.com
3 months ago
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by Commercial and Development Partners - - Use of Suprachoroidal Drug Delivery Featured in Over 15 Presentations at Major Ophthalmic Medical Meetings This Year - ALPHARETTA, Ga., May 14, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.
globenewswire.com
3 months ago
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases
globenewswire.com
3 months ago
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.
See all news
